NA-831

1. NA-831 improves cognitive function in humans (4.1-point improvement, p = 0.001).

   “NA‐831 treatment resulted in a significant cognitive improvement in AD patients, with a mean 4.1‐point improvement on the ADAS‐Cog‐13 scale compared to placebo (p = 0.001).”

   Human trialAlzheimer's diseaseoral24 weeks

   Neuro‐Metabolic Association in Alzheimer’s Disease and Obesity: Clinical Evaluation of NA‐831 and NA‐931

   AAIC 2025 abstract·23 Dec 2025

1. NA-831 decreases body weight in humans (up to 13.7% in 66% of patients).

   “66% patients having diabetes on the NA-831 drug treatment reported a loss of up to 13.7% of body weight over 6 months.”

   Human trialdiabetes and AD6 months

   Associations between Alzheimer's Disease (AD) and Obesity—Clinical Trials of NA-813 for AD and NA-931 for Obesity

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

1. NA-831 improves CIBIC-Plus in humans (78%, p = 0.01).

   “CIBIC-Plus showed 78 % patients improved (p = 0.01; ITT).”

   Human trialmild and moderate AD24 weeks

   Associations between Alzheimer's Disease (AD) and Obesity—Clinical Trials of NA-813 for AD and NA-931 for Obesity

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on CIBIC-Plus

1. NA-831 improves ADAS-Cog-13 in humans (average change 4.1 vs placebo, p = 0.001).

   “ADAS-Cog-13 score change of an average of 4.1 as compared to the placebo after 24 weeks of treatment (p = 0.001; ITT)”

   Human trialmild and moderate AD24 weeks

   Associations between Alzheimer's Disease (AD) and Obesity—Clinical Trials of NA-813 for AD and NA-931 for Obesity

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on ADAS-Cog-13